JP2016520521A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520521A5
JP2016520521A5 JP2016502262A JP2016502262A JP2016520521A5 JP 2016520521 A5 JP2016520521 A5 JP 2016520521A5 JP 2016502262 A JP2016502262 A JP 2016502262A JP 2016502262 A JP2016502262 A JP 2016502262A JP 2016520521 A5 JP2016520521 A5 JP 2016520521A5
Authority
JP
Japan
Prior art keywords
antibody
formulation
protein
oxidation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520521A (ja
JP6389236B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026841 external-priority patent/WO2014160495A1/en
Publication of JP2016520521A publication Critical patent/JP2016520521A/ja
Publication of JP2016520521A5 publication Critical patent/JP2016520521A5/ja
Application granted granted Critical
Publication of JP6389236B2 publication Critical patent/JP6389236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502262A 2013-03-13 2014-03-13 酸化還元製剤 Active JP6389236B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780845P 2013-03-13 2013-03-13
US61/780,845 2013-03-13
US201361909813P 2013-11-27 2013-11-27
US61/909,813 2013-11-27
PCT/US2014/026841 WO2014160495A1 (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018083450A Division JP2018150317A (ja) 2013-03-13 2018-04-24 酸化還元製剤

Publications (3)

Publication Number Publication Date
JP2016520521A JP2016520521A (ja) 2016-07-14
JP2016520521A5 true JP2016520521A5 (cg-RX-API-DMAC7.html) 2018-06-14
JP6389236B2 JP6389236B2 (ja) 2018-09-12

Family

ID=51625442

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502262A Active JP6389236B2 (ja) 2013-03-13 2014-03-13 酸化還元製剤
JP2018083450A Withdrawn JP2018150317A (ja) 2013-03-13 2018-04-24 酸化還元製剤
JP2020091966A Pending JP2020164531A (ja) 2013-03-13 2020-05-27 酸化還元製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018083450A Withdrawn JP2018150317A (ja) 2013-03-13 2018-04-24 酸化還元製剤
JP2020091966A Pending JP2020164531A (ja) 2013-03-13 2020-05-27 酸化還元製剤

Country Status (23)

Country Link
EP (1) EP2968466B1 (cg-RX-API-DMAC7.html)
JP (3) JP6389236B2 (cg-RX-API-DMAC7.html)
KR (1) KR102237885B1 (cg-RX-API-DMAC7.html)
CN (2) CN110075293A (cg-RX-API-DMAC7.html)
AU (3) AU2014243700B2 (cg-RX-API-DMAC7.html)
CA (2) CA3113172A1 (cg-RX-API-DMAC7.html)
DK (1) DK2968466T3 (cg-RX-API-DMAC7.html)
ES (1) ES2688895T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181504T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039948T2 (cg-RX-API-DMAC7.html)
IL (2) IL269947B (cg-RX-API-DMAC7.html)
LT (1) LT2968466T (cg-RX-API-DMAC7.html)
MX (2) MX369671B (cg-RX-API-DMAC7.html)
MY (2) MY174679A (cg-RX-API-DMAC7.html)
NZ (1) NZ711566A (cg-RX-API-DMAC7.html)
PL (1) PL2968466T3 (cg-RX-API-DMAC7.html)
PT (1) PT2968466T (cg-RX-API-DMAC7.html)
RS (1) RS57813B1 (cg-RX-API-DMAC7.html)
RU (1) RU2707092C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201507043SA (cg-RX-API-DMAC7.html)
SI (1) SI2968466T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014160495A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201506876B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
EP2968467B1 (en) * 2013-03-13 2020-06-03 F.Hoffmann-La Roche Ag Formulations with reduced oxidation
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA45450B1 (fr) 2016-06-27 2021-04-30 Morphosys Ag Formulations d'anticorps anti-cd19
US20200254123A1 (en) * 2017-10-13 2020-08-13 Tamura Teco Co., Ltd. Harmful substance treatment method and ozone generating device
KR102898177B1 (ko) 2018-08-08 2025-12-10 제넨테크, 인크. 단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン コーポレーション Hiv感染治療のための異種複合抗体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2332893T3 (es) 1996-08-30 2010-02-15 Upfront Chromatography A/S Aislamiento de inmunoglobulinas.
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1167537B1 (en) 1999-03-30 2008-07-23 Japan Tobacco Inc. Process for producing monoclonal antibody
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
WO2002022573A2 (en) * 2000-09-15 2002-03-21 The Scripps Research Institute Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
WO2002092017A2 (en) 2001-05-16 2002-11-21 Albert Einstein College Of Medicine Of Yeshiva University Human antipneumococcal antibodies from non-human animals
EP1425389B1 (en) 2001-08-23 2011-11-02 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
JP4342941B2 (ja) * 2001-08-29 2009-10-14 中外製薬株式会社 抗体含有安定化製剤
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20060258841A1 (en) 2003-01-17 2006-11-16 Josef Michl Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7456264B2 (en) 2003-05-21 2008-11-25 Medarex, Inc. Human monoclonal antibodies against Bacillus anthracis protective antigen
AU2004321117B2 (en) * 2003-12-18 2010-09-02 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
JP2007319124A (ja) * 2006-06-02 2007-12-13 Nippon Tablet Kk 健康食品
US8431552B2 (en) * 2007-01-16 2013-04-30 Chien-Hung Chen Composition for treating metabolic syndrome
ES2628407T3 (es) * 2008-04-01 2017-08-02 Antipodean Pharmaceuticals, Inc. Composiciones y procedimientos para el cuidado de la piel
DK2321640T3 (en) * 2008-08-21 2017-02-27 Immunogenics Llc FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
JP5705115B2 (ja) * 2008-09-10 2015-04-22 ジェネンテック, インコーポレイテッド 蛋白質の酸化的分解の予防のための組成物および方法
EP2331090B1 (en) * 2008-09-19 2018-01-03 Pfizer Inc. Stable liquid antibody formulation
KR102058307B1 (ko) * 2010-06-24 2019-12-20 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
RU2447448C1 (ru) * 2010-08-30 2012-04-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" Способ стабилизации антител в водных растворах
WO2012170883A1 (en) * 2011-06-09 2012-12-13 Discovery Pharma Consulting, Llc Antihistamines combined with dietary supplements for improved health
US9321848B2 (en) * 2011-06-28 2016-04-26 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide

Similar Documents

Publication Publication Date Title
US20230181533A1 (en) Formulations with reduced oxidation
AU2019202464B2 (en) Formulations with reduced oxidation
JP2019167349A (ja) 酸化還元製剤
JP2016520521A5 (cg-RX-API-DMAC7.html)
US10653779B2 (en) Formulations with reduced oxidation
NZ751543B2 (en) Formulations with reduced oxidation
BR112015022484B1 (pt) Formulação líquida, seu método de produção, e método para impedir a oxidação de uma proteína na dita formulação líquida
HK1211219B (zh) 氧化降低的配制剂